- Home
- CAPS vs RNAZ Comparison
CAPS vs RNAZ Comparison
Compare CAPS & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPS
- RNAZ
- Stock Information
- Founded
- CAPS 1987
- RNAZ 2016
- Country
- CAPS United States
- RNAZ United States
- Employees
- CAPS N/A
- RNAZ N/A
- Industry
- CAPS
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- CAPS
- RNAZ Health Care
- Exchange
- CAPS NYSE
- RNAZ Nasdaq
- Market Cap
- CAPS 7.4M
- RNAZ 6.1M
- IPO Year
- CAPS N/A
- RNAZ 2021
- Fundamental
- Price
- CAPS $1.60
- RNAZ $11.74
- Analyst Decision
- CAPS
- RNAZ Strong Buy
- Analyst Count
- CAPS 0
- RNAZ 1
- Target Price
- CAPS N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- CAPS 93.7K
- RNAZ 238.4K
- Earning Date
- CAPS 04-02-2025
- RNAZ 08-13-2025
- Dividend Yield
- CAPS N/A
- RNAZ N/A
- EPS Growth
- CAPS N/A
- RNAZ N/A
- EPS
- CAPS N/A
- RNAZ N/A
- Revenue
- CAPS $43,416,000.00
- RNAZ N/A
- Revenue This Year
- CAPS $7.87
- RNAZ N/A
- Revenue Next Year
- CAPS N/A
- RNAZ N/A
- P/E Ratio
- CAPS N/A
- RNAZ N/A
- Revenue Growth
- CAPS N/A
- RNAZ N/A
- 52 Week Low
- CAPS $1.30
- RNAZ $6.15
- 52 Week High
- CAPS $16.18
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- CAPS N/A
- RNAZ 67.96
- Support Level
- CAPS N/A
- RNAZ $9.02
- Resistance Level
- CAPS N/A
- RNAZ $17.24
- Average True Range (ATR)
- CAPS 0.00
- RNAZ 1.28
- MACD
- CAPS 0.00
- RNAZ 0.31
- Stochastic Oscillator
- CAPS 0.00
- RNAZ 40.21
About CAPS CAPSTONE HOLDING CORP
Capstone Holding Corp is a building products distribution network. The existing network is comprised of Instone, a distributor of thin veneer stone and related masonry products in the United States, serving both residential and commercial construction markets. The company's product offering includes manufactured and natural stone products, supported by a distribution network. The company's current products include stone veneer, landscape stone, and modular masonry fireplaces.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.